

**Korea DPR
Support for Measles-Rubella Vaccine**

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Korea DPR		
2. Grant number: 19-PRK-18d-X / 19-PRK-35b-Y		
3. Date of Decision Letter: 22 March 2019		
4. Date of the Partnership Framework Agreement: 7 June 2013		
5. Programme title: New Vaccine Support (NVS), Measles-Rubella Catch-up Campaign		
6. Vaccine type: Measles-Rubella		
7. Requested product presentation and formulation of vaccine: Measles Rubella, 10 dose(s) per vial, LYOPHILISED		
8. Programme duration¹: 2019		
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement)		
	2019	Total ²
Programme Budget (US\$)	4,861,000	4,861,000
10. Vaccine introduction grant (in US\$): Not applicable		
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ³		
Type of supplies to be purchased with Gavi funds in each year	2019	
Number of Measles-Rubella vaccines doses	7,465,900	
Annual Amounts (US\$)	4,861,000	
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.		
13. Self-procurement: Not applicable		
14. Co-financing obligations: Not applicable		

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the amount that Gavi has approved.

15. Operational support for campaigns: The support for operational costs for campaign will be disbursed in cash through WHO/UNICEF. The Country will need to contact the local WHO/UNICEF office to arrange the utilisation of GAVI funds to support the operational costs of the campaign.

	2019
Grant amount (US\$)	4,371,872

16. Additional reporting requirements:

Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future annual amounts:

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. 	31 March 2019 15 May 2019
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
Supplementary Immunisation Activity (SIA) technical report	Within 3 months of end of campaign
Post campaign coverage survey report	As soon as available

17. Financial clarifications: Not applicable

18. Other conditions: As a condition to Gavi's support for measles and rubella, country will be required to fully self-finance with domestic resources the measles component of the first dose of measles containing vaccine (MCV1) in its national immunisation programme.

Signed by,



On behalf of Gavi

Hind Khatib-Othman
Managing Director, Country Programmes
22 March 2019